Bpifrance Life Sciences Venture
Investor profile | Builders Republic
About
Bpifrance Life Sciences Venture (InnoBio 2 & Patient Autonome) — Bpifrance’s health-focused VC activity spanning biotech/medtech and digital health: - InnoBio 2 (launched 2019) backs early‑ to mid‑stage therapeutics and enabling technologies with initial commitments up to ~€14m; first close was €135m with a target fund size of €200–250m, subscribed by Bpifrance, Sanofi and several pharma groups (incl. Boehringer Ingelheim, Ipsen, Servier, Takeda; later joined by Bristol Myers Squibb). - Patient Autonome (launched 2018) invests Seed to Series A in digital‑health solutions improving care pathways and access; the fund was doubled in 2021 to €100m, with typical first tickets of €0.5–3m and up to €8m per company over time.
Key facts
- Type
- Public Fund / Sovereign Wealth Fund
- Stages
- Series A,Series B
- Sectors
- Life sciences,Biotech,Healthcare
- Headquarters
- France
- Offices
- Paris
- Geographic focus
- France,Europe
- Lead / Follow
- Can lead and follow
- Ticket size
- 3M€ – 10M€
- Assets under management
- 800M€
- Founded
- 2009
Track record
- Total investments: 56
- Exits: 16
Notable investments in France
Hepta Medical, UroMems, May Health
Key differentiators
Evergreen,Public funds,Sector Specialist